Arecor Employs Excipients for Biologics Stability



When biologics took center stage in the pharmaceutical development pipeline, Thomas Reese Saylor, president and CEO of Arecor, realized that developers needed new approaches to drug formulation. As he tells GEN, "When pharmaceutical pipelines were dominated by small molecules, formulation was considered only when drugs were in the later stages of development. But with biologics, formulation must be considered at the beginning. If there’s no stable formulation, there’s no product."

The full article is available here.